WEBULL
WebtradeDownload

Is Afya (AFYA) A Bargain As It Reaffirms 2026 Revenue Guidance?

Simply Wall St · 1d ago

Afya (NasdaqGS:AFYA) is back in focus after its latest earnings release for the quarter and first half of 2026, alongside a reaffirmed full year revenue guidance range of BRL 3,950 million to BRL 4,100 million.

See our latest analysis for Afya.

Afya’s latest reaffirmed revenue guidance and first half 2026 earnings sit against a share price that has eased in recent months, with the 30 day share price return down 4.56% and the 1 year total shareholder return down 9.19%. This points to weaker momentum, despite earlier periods showing a smaller 3 year total shareholder return decline of 2.64% compared with a 5 year total shareholder return decline of 30.19%.

If Afya’s recent moves have you thinking about where else growth stories and rerating potential might be building, it can help to widen the lens beyond a single stock. One practical next step is to scan the market using the 20 top founder-led companies

Afya now trades at a clear discount to both analyst targets and an estimated intrinsic value, even after reaffirming guidance and posting higher first half earnings. Is the market’s caution grounded in risk, or is it mispricing the story?

Most Popular Narrative: 22.3% Undervalued

Afya’s most followed narrative points to a fair value of $17.25 against a last close of $13.41, which implies a clear valuation gap that hinges on how earnings, margins and capital returns play out over time.

Digital initiatives and cross-segment integration, including Medical Practice Solutions and Continuing Education, are increasing recurring, higher-margin digital revenues and operational synergies, which is expected to support sustained net margin expansion and greater earnings stability.

Read the complete narrative.

Want to see what sits behind that earnings picture for Afya? The narrative focuses on compounding revenue, firmer margins and a future profit multiple that compares with many consumer services peers. Curious how those moving parts combine into a single fair value number?

Result: Fair Value of $17.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Afya’s narrative can change quickly if competition for medical students pressures tuition or if higher effective tax rates compress margins more than expected.

Find out about the key risks to this Afya narrative.

Next Steps

With Afya’s story pulling in both optimism and caution, it makes sense to look at the full picture yourself and decide quickly where you stand using the 5 key rewards and 1 important warning sign

Looking for more Afya investment ideas?

If Afya has sparked your interest, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that could fit your approach before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.